Differences in tumor type in low-stage versus high-stage ovarian carcinomas

International Journal of Gynecological Pathology

Volumn 29, Issue 3, 2010, Pages 203-211

  Köbel, Martin ^a   Kalloger, Steve E ^b   Huntsman, David G ^b   Santos, Jennifer L ^c   Swenerton, Kenneth D ^c   Seidman, Jeffrey D ^d   Gilks, C Blake ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c Canada Cheryl Brown Ovarian Cancer Outcomes Unit   (Canada)

^d WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Cancer; Ovarian carcinoma; Ovary; Stage; Type

Indexed keywords

MUCIN;

ARTICLE; CANCER CLASSIFICATION; CANCER RISK; CANCER STAGING; CLEAR CELL CARCINOMA; ENDOMETRIOID CARCINOMA; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR DIFFERENTIATION;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; BRITISH COLUMBIA; CARCINOMA, ENDOMETRIOID; COHORT STUDIES; CYSTADENOCARCINOMA, SEROUS; DISTRICT OF COLUMBIA; FEMALE; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 77951702294     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/PGP.0b013e3181c042b6     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Seidman JD, Horkayne-Szakaly I, Haiba M, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004;23:41-44
3. Gilks CB, Ionescu D, Kalloger SE, et al. Tumor cell type can reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 2008;39:1239-1251
4. Gilks CB. Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol 2004;23:200-205
5. Kobel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008;5:e232.
6. Mink PJ, Sherman ME, Devesa SS. Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States. Results from the SEER Program, 1978-1998. Cancer 2002;95:2380-2389
7. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, et al. Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res 2004;10:4427-4436
8. Sakamoto A, Sasaki H, Furusato M, et al. Observer disagreement in histological classification of ovarian tumors in Japan. Gynecol Oncol 1994;54:54-58
9. Kommoss F, Kommoss S, Schmidt D, et al. Survival benefit for patients with advanced-stage transitional cell carcinomas versus other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel. Gynecol Oncol 2005;97:195-199
10. Faggad A, Darb-Esfahani S, Wirtz R, et al. Topoisomerase II alpha mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis. Mod Pathol 2009;22:579-588
11. Davidson B, Elstrand MB, McMaster MT, et al. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecol Oncol 2005;96: 42-47
12. Abell MR. The nature and classification of ovarian neoplasms. Can Med Assoc J 1966;94:1102-1124
13. Scully RE, Barlow JF. "Mesonephroma" of ovary. Tumor of Mullerian nature related to the endometrioid carcinoma. Cancer 1967;20:1405-1417
14. Aure JC, Hoeg K, Kolstad P. Clinical and histologic studies of ovarian carcinoma. Long-term follow-up of 990 cases. Obstet Gynecol 1971;37:1-9.
15. Silva EG, Tornos C, Bailey MA, et al. Undifferentiated carcinoma of the ovary. Arch Pathol Lab Med 1991;115:377-381
16. Tavasolli FA, Devilee P. World Health Organization Classification of Tumours. Tumours of the Breast and the Female Genital Organs. Lyon, France: IARCPress-WHO; 2003.
17. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 2003;27:985-993
18. Shimizu M, Toki T, Takagi Y, et al. Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol 2000;19:158-163
19. Kobel M, Kalloger SE, Carrick J, et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 2009;33:14-21.
20. Malpica A, Deavers MT, Tornos C, et al. Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol 2007;31:1168-1174
21. Singer G, Stohr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and highgrade carcinomas and provide support for a new model of ovarian carcinogenesis: A mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005;29:218-224
22. Soslow RA. Histologic subtypes of ovarian carcinoma: An overview. Int J Gynecol Pathol 2008;27:161-174
23. Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol 2009;40:1213-1223.
24. Han G, Gilks CB, Leung S, et al. Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: An interobserver correlative and immunohistochemical study of 32 cases. Am J Surg Pathol 2008; 32:955-964
25. Shimizu Y, Kamoi S, Amada S, et al. Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features-problems involved in the architectural grading system. Gynecol Oncol 1998;70:2-12.
26. Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004;28: 496-504.
27. Salvador S, Gilks B, Kobel M, et al. The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer 2009;19:58-64.
28. Crum CP, Drapkin R, Miron A, et al. The distal fallopian tube: A new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007;19:3-9. (Pubitemid 46095865)
29. Yemelyanova AV, Cosin JA, Bidus MA, et al. Pathology of stage I versus stage III ovarian carcinoma with implications for pathogenesis and screening. Int J Gynecol Cancer 2008;18:465-469
30. Leitao MM Jr, Boyd J, Hummer A, et al. Clinicopathologic analysis of early-stage sporadic ovarian carcinoma. Am J Surg Pathol 2004;28:147-159
31. Kyrgiou M, Salanti G, Pavlidis N, et al. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst 2006;98:1655-1663
32. Kobel M, Gilks CB, Huntsman DG. Dicer and Drosha in ovarian cancer. N Engl J Med 2009;360:1150-1151
33. Schmeler KM, Gershenson DM. Low-grade serous ovarian cancer: A unique disease. Curr Oncol Rep 2008;10:519-523
34. Silva EG, Deavers MT, Bodurka DC, et al. Association of lowgrade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: A new type of dedifferentiated carcinoma? Int J Gynecol Pathol 2006;25:52-58
35. Brown PO, Palmer C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med 2009;6:e1000114.
36. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009;10:327-340
37. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000;88:2584-2589
38. duBois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as firstline treatment of ovarian cancer. J Natl Cancer Inst 2003;95: 1320-1329
39. Bose CK. Is randomized trial of neoadjuvant chemotherapy of ovarian cancer necessary? Gynecol Oncol 2009;114:371-372